BS_G7AGNB5G
low-grade glioma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- low-grade glioma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- low-grade glioma
- overall_survival_months
- 49.40867279894875
- age_years
- 12.211
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.257
- FATTY_ACID_METABOLISM+0.161
- BILE_ACID_METABOLISM+0.152
- WNT_BETA_CATENIN_SIGNALING+0.143
- PEROXISOME+0.142
- ADIPOGENESIS+0.138
- MITOTIC_SPINDLE+0.108
- NOTCH_SIGNALING+0.068
- SPERMATOGENESIS+0.068
- PROTEIN_SECRETION+0.053
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.494
- IL6_JAK_STAT3_SIGNALING-0.490
- TNFA_SIGNALING_VIA_NFKB-0.478
- INFLAMMATORY_RESPONSE-0.401
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.400
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.394
- APOPTOSIS-0.382
- INTERFERON_GAMMA_RESPONSE-0.381
- IL2_STAT5_SIGNALING-0.377
- MYC_TARGETS_V2-0.372
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_FWMJPKCV | DNET | — | 0.921 |
| 2 | MBCProject_0004_T1_RNA | — | C | 0.870 |
| 3 | BS_A46RDWGM | low-grade glioma | — | 0.861 |
| 4 | BS_67Z63A2K | EPN | Posterior Fossa EPN | 0.857 |
| 5 | BS_264RCK7G | DNET | — | 0.845 |
| 6 | DRR168589 | — | — | 0.840 |
| 7 | SJEPD031319_D1.RNA-Seq | EPN | EPN Tumor | 0.833 |
| 8 | SRR5088848 | — | — | 0.832 |
| 9 | BS_68BW2163 | low-grade glioma | — | 0.829 |
| 10 | SRR15069618 | — | — | 0.817 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.257 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.161 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.152 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.143 | Inavolisib | — uncovered |
| PEROXISOME | 0.142 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.138 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.108 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.068 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.068 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.053 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.008 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.006 | Inavolisib | — uncovered |